In Brief: Trinity Biotech/Centocor
This article was originally published in The Gray Sheet
Executive Summary
Trinity Biotech/Centocor: Ink agreement under which Trinity Biotech will purchase Centocor's U.K.-based infectious disease business for $5.5 mil. Trinity Biotech acquires several microtitre enzyme immunoassay tests, including tests for toxoplasmosis, rubella, cytomegalovirus, herpes simplex virus 2, syphilis, and Chagas disease. Trinity also gains a Centocor diagnostic manufacturing facility in Guildford, England. Centocor will record a $4.5 mil. charge to earnings in connection with the transaction, which is expected to close within the next month...